Increased sedentary lifestyles, unhealthy eating habits, and aging populations are key contributors to rising disease incidence
Some individuals also experience side effects
Participants who were pregnant or breastfeeding or treated with nebulized NAC, newly prescribed mucoactive drugs, or subjected to changes in mucoactive drugs dosage within 4 weeks of treatment, and those with a history of hypersensitivity to NAC or contraindications for NAC, were excluded
GLP-1 itself exemplifies this phenomenon, as early native peptide formulations required continuous infusion to achieve sustained efficacy
According to the FDA-approved prescribing information for Wegovy (semaglutide, current label on file with the FDA as of 2026) and Zepbound (tirzepatide, current label on file with the FDA as of 2026), both carry these warnings: A boxed warning - the FDA's most serious warning category - for thyroid C-cell tumors observed in rodent studies